Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Front Immunol. 2022 Mar 25;13:842439. doi: 10.3389/fimmu.2022.842439. eCollection 2022.
The incidence of diffuse large B-cell lymphoma (DLBCL) increases by age and older DLBCL are commonly related to poor prognosis. However, the clinical and biological features of older DLBCL patients remain to be determined. A total of 2,445 patients with newly diagnosed DLBCL were enrolled for clinical data analysis according to age at diagnosis, with tumor samples of 1,150 patients assessed by DNA sequencing and 385 patients by RNA sequencing. Older DLBCL presented advanced disease stage, elevated serum lactate dehydrogenase, poor performance status, multiple extranodal involvement, high percentage of double expressor subtype, and adverse clinical outcome. According to molecular features, age was positively correlated with the oncogenic mutations of , , , , , , , , and with the MYD88-like genetic subtype. These oncogenic mutations were involved in B-cell receptor/NF-κB signaling, B-cell differentiation, and histone acetylation based on biological functions. Older DLBCL also manifested reduction in CD4 naïve T and CD8 naïve T cells, and also increased recruitment of exhausted T cells and macrophages, leading to immunosuppressive tumor microenvironment. Our work thus contributes to the understanding of aging-related oncogenic mutations and tumor microenvironment alterations in lymphoma progression, and may provide new insights to mechanism-based targeted therapy in DLBCL.
弥漫性大 B 细胞淋巴瘤(DLBCL)的发病率随年龄增长而增加,年龄较大的 DLBCL 通常与预后不良有关。然而,年龄较大的 DLBCL 患者的临床和生物学特征仍有待确定。根据诊断时的年龄,共纳入 2445 例新诊断的 DLBCL 患者进行临床数据分析,其中 1150 例患者的肿瘤样本进行了 DNA 测序评估,385 例患者进行了 RNA 测序评估。年龄较大的 DLBCL 表现为晚期疾病分期、血清乳酸脱氢酶升高、表现状态不佳、多个结外累及、双表达亚型比例高以及不良临床结局。根据分子特征,年龄与 、 、 、 、 、 、 和 MYD88 样遗传亚型的致癌突变呈正相关。这些致癌突变涉及 B 细胞受体/NF-κB 信号、B 细胞分化和组蛋白乙酰化,基于生物学功能。年龄较大的 DLBCL 还表现出幼稚 CD4 T 细胞和幼稚 CD8 T 细胞减少,以及耗竭 T 细胞和巨噬细胞募集增加,导致免疫抑制性肿瘤微环境。因此,我们的工作有助于了解淋巴瘤进展中与衰老相关的致癌突变和肿瘤微环境改变,并可能为 DLBCL 的基于机制的靶向治疗提供新的见解。